First-in-human study uses universal donor 'natural killer cells' to treat acute myeloid leukemia
(Ohio State University Wexner Medical Center) A new, phase I clinical trial offered The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) will treat patients with relapsed or refractory acute myeloid leukemia (AML) using a novel universal natural killer cell approach. The trial will be conducted in partnership with Kiadis, a clinical stage biopharmaceutical company. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 27, 2020 Category: International Medicine & Public Health Source Type: news
FDA D.I.S.C.O.: A new drug approval for IDH1 positive relapsed or refractory Acute Myeloid Leukemia
FDA medical oncologists discuss the July 2018 approval of ivosidenib for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Initial FLAG-Ida Outperforms 7+3 for High-Risk AML Initial FLAG-Ida Outperforms 7+3 for High-Risk AML
A treatment commonly used as a salvage regimen for relapsed/refractory acute myelogenous leukemia (AML) showed better results than did standard treatment when used as initial induction therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
CDI laboratory explores pathway to open up blood cancer treatments
(Hackensack Meridian Health) The CDI team's findings could ultimately improve cancer treatments for people of advanced age, like that of adult acute myeloid leukemia (AML). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 14, 2020 Category: Cancer & Oncology Source Type: news
Bright idea in dentist's office leads to innovative smoking cessation project
Results from this study recently published online in Addiction found primary care physicians providing smokers with a free, two week starter kit of nicotine replacement therapy (NRT) increased quit attempts While sitting in the dentist ' s office, Hollings Cancer Center researcher Matthew Carpenter, Ph.D., of the Medical University of South Carolina, had a bright idea. As he received his goody bag with dental hygiene products, he wondered why not conduct a study and have primary care providers do the same thing for their patients who use tobacco. The bags would contain educational material, free lozenges and tobacco ces...
Source: Dental Technology Blog - February 12, 2020 Category: Dentistry Source Type: news
FDA Lifts Clinical Hold for MultiTAA T-Cell Therapy Trial in Acute Myeloid Leukemia
The planned trial will investigate the safety and efficacy of the novel multi-tumor associated antigen T-cell therapy in patients with post-transplant acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 12, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’r...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
The initiating mutations that contribute to cancer development are sometimes present in premalignant cells. Whether therapies targeting these mutations can eradicate premalignant cells is unclear. Acute myeloid leukemia (AML) is an attractive system for investigating the effect of preventative treatment because this disease is often preceded by a premalignant state (clonal hematopoiesis or myelodysplastic syndrome). In Npm1c/Dnmt3a mutant knock-in mice, a model of AML development, leukemia is preceded by a period of extended myeloid progenitor cell proliferation and self-renewal. We found that this self-renewal can be reve...
Source: ScienceNOW - January 29, 2020 Category: Science Authors: Uckelmann, H. J., Kim, S. M., Wong, E. M., Hatton, C., Giovinazzo, H., Gadrey, J. Y., Krivtsov, A. V., Rücker, F. G., Döhner, K., McGeehan, G. M., Levine, R. L., Bullinger, L., Vassiliou, G. S., Armstrong, S. A. Tags: Medicine, Diseases reports Source Type: news
Cheap drug may alleviate treatment-resistance in leukemia
(Karolinska Institutet) A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human blood cells performed at Karolinska Institutet and SciLifeLab and published in the medical journal EMBO Molecular Medicine. The researchers will now launch a clinical study to test the new combination treatment in patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 17, 2020 Category: International Medicine & Public Health Source Type: news
A solid vaccine for liquid tumors
(Wyss Institute for Biologically Inspired Engineering at Harvard) Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years. Chemotherapy has been the standard treatment for over 40 years, and while it often causes the cancer to go into remission, nearly half of patients experience disease relapse. Scientists at the Wyss Institute and Harvard SEAS have developed an injectable, biomaterial-based vaccine that, when combined with standard chemotherapy, caused complete and lasting recovery from and immunity against AML in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 14, 2020 Category: Cancer & Oncology Source Type: news
Vitamin B6, leukemia's deadly addiction
Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The research team from Cold Spring Harbor Laboratory (CSHL) and Memorial Sloan Kettering Cancer Center (MSK) suggest they could halt the growth of this cancer by limiting its ability to manipulate the enzyme that pushes B6 to make proteins essential for cell division. (Source: World Pharma News)
Source: World Pharma News - January 13, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Vitamin B6, leukemia's deadly addiction
(Cold Spring Harbor Laboratory) Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6. Now that researchers know this, they can pursue new treatment options for the deadly blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 13, 2020 Category: Cancer & Oncology Source Type: news
Naval Daver, MD, Provides Perspective on Updates in Acute Myeloid Leukemia
Naval Daver, MD, explains the progress made on 3 abstracts he ’s involved with regarding acute myeloid leukemia (AML) at the ASH Annual Meeting and Exposition. (Source: CancerNetwork)
Source: CancerNetwork - January 12, 2020 Category: Cancer & Oncology Authors: Naval Daver, MD Source Type: news
Courtney DiNardo, MD, MSCE, on Enasidenib Plus Azacitidine in Newly Diagnosed AML
Courtney DiNardo, MD, MSCE, elaborated on interim phase II results regarding enasibenib plus azacitidine in patients with newly diagnosed acute myeloid leukemia, and the results from the QUAZAR trial. (Source: CancerNetwork)
Source: CancerNetwork - January 10, 2020 Category: Cancer & Oncology Authors: Courtney DiNardo, MD, MSCE Source Type: news
Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.
Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment.
Germantown’s Precigen Inc. has earned orphan drug status from the Food and Drug Administration for its therapy for relapsed or refractory acute myeloid leukemia, a form of cancer in the blood and bone marrow, in cases that have either come back or failed to respond to past treatment. The company … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 6, 2020 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news
